Research-grade biosimilars
Briakinumab, Nimotuzumab, Mogamulizumab, Epratuzumab, Felvizumab, Lintuzumab, Galiximab, Tocilizumab, Drozitumab, Efungumab, Neuradiab, Pateclizumab, Nivolumab, Cetuximab
Anti-VEGF (Bevacizumab), humanized Antibody
Anti-HER2 (Trastuzumab), humanized Antibody
Anti-EGFR (Cetuximab), Chimeric Antibody
Anti-TNF-α (Adalimumab), humanized Antibody
Anti-CD20 (Rituximab), Chimeric Antibody
Anti-EGFR (Panitumumab), humanized antibody
Anti-OX40L (Oxelumab), Human IgG1 Antibody
Anti-CD11a (Efalizumab), Human IgG1 Antibody
Anti-EGFR (Matuzumab), Human IgG1 Antibody
Anti-CD4 (Clenoliximab), Human IgG4 Antibody
Anti-alpha 5 beta 1 Integrin (Volociximab), Human IgG4 Antibody
Anti-TNF alpha (Humicade), Human IgG4 Antibody
Anti-CD40L (Ruplizumab), Human IgG1 Antibody
Anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Antibody
Anti-TNF alpha (Infliximab), Human IgG1 Antibody
Anti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody
Anti-IL-2R alpha (Daclizumab), Human IgG1 Antibody
Anti-CD52 (Campath-1H), Human IgG1 Antibody
Zika
Anti-Zika virus antibodies – Clones ZKA64, ZKA78 & 4G2
Anti-E-protein DIII (ABDE) [ZV-2]
Anti-E-protein DIII (C-C’) [ZV-48]
Anti-E-protein DIII (C-C’) [ZV-64]
Anti-E-protein DIII (LR) [ZV-67]
Anti-Envelope protein [ZKA64]
Anti-Envelope protein [ZKA78]
Anti-Flavivirus group antigen [D1-4G2-4-15 (4G2)]